Disease area and mode of action as criteria to assign a default occupational exposure limit.


Journal

Regulatory toxicology and pharmacology : RTP
ISSN: 1096-0295
Titre abrégé: Regul Toxicol Pharmacol
Pays: Netherlands
ID NLM: 8214983

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 27 03 2020
revised: 06 12 2020
accepted: 09 02 2021
pubmed: 16 2 2021
medline: 17 11 2021
entrez: 15 2 2021
Statut: ppublish

Résumé

In the early stages of drug research and development, there are only a few or no toxicological data available for newly synthesized small molecule drug candidates (DC). Calculation of the DC's occupational exposure limit (OEL) without toxicological data is not possible. Nevertheless, an OEL is needed to indicate the level of protection required to minimize risks for laboratory researchers and technicians. For this reason, simplified guidance is required to predict possible health hazards of DCs and their corresponding safe inhalation exposure levels. Here, we evaluated 860 drug substances (DS) with OELs calculated by Novartis and grouped the DSs by disease area (DA) and then their mode of action (MoA). 28% of the evaluated DSs (n = 242) had an OEL <10 μg/m

Identifiants

pubmed: 33587935
pii: S0273-2300(21)00031-3
doi: 10.1016/j.yrtph.2021.104891
pii:
doi:

Substances chimiques

Drugs, Investigational 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104891

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Milica Glogovac (M)

Novartis Pharma AG, Novartis Business Services, Postfach, CH-4002, Basel, Switzerland. Electronic address: milica.glogovac@novartis.com.

Caylee Paulson (C)

Novartis Pharma AG, Novartis Business Services, Postfach, CH-4002, Basel, Switzerland. Electronic address: caylee.paulson@novartis.com.

Amy Lambert (A)

Novartis Institutes for BioMedical Research, Cambridge, USA; Roche Innovation Center Zurich, Wagistrasse 10, CH-8952, Schlieren, Switzerland. Electronic address: amy_letitia.lambert@roche.com.

Gian Christian Winkler (GC)

Novartis Pharma AG NIBR, Postfach, CH-4002, Basel, Switzerland; Preclinical Safety Consultant, In den Reben 229, CH-5063, Oberhof, Switzerland. Electronic address: winkgu@vtxnet.ch.

Ester Lovsin Barle (E)

Novartis Pharma AG, Novartis Business Services, Postfach, CH-4002, Basel, Switzerland; Takeda Pharmaceutical Company Limited, Thurgauerstrasse 130, CH-8152, Glattpark (Opfikon), Switzerland. Electronic address: ester.lovsin-barle@takeda.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH